

# *Welcome to today's FDA/CDRH Webinar*

*Thank you for your patience while additional time is  
provided for participants to join the call.*

**Please connect to the audio portion of the webinar  
now:**

**US Callers: 888-233-1204**

**International Callers: 1-773-799-3794**

**Passcode: 7278970**

# 510(k) Third Party Review Program

J. Allen Hill  
Physicist/Policy Analyst

Division of Program Operations and Management  
Office of In Vitro Diagnostics and Radiological Health  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

April 16, 2020

# Agenda

- Objectives
- Background
- Eligibility Factors for Devices
- How 510(k) Third Party (3P510k) Review Organizations should review files
- Recognition and Rerecognition of 3P510k Review Organizations
- Suspension or Recognition Withdrawal
- Leveraging International Harmonization

# Objectives

- Provide an overview of the 510(k) Third Party Review Program
- Identify eligible devices
- Recognize elements of an FDA-equivalent review
- Review key actions for 3P510k Review Organizations



# Background

Delivers on  
MDUFA IV Commitment

12/02/2016  
Page 1

**MDUFA PERFORMANCE GOALS AND PROCEDURES,  
FISCAL YEARS 2018 THROUGH 2022**

General	1
I. Shared Outcome Goals	1
A. PMA	1
B. 510(k)	1
II. Review Performance Goals - Fiscal Years 2018 Through 2022 As Applied to Receipt Cohorts	3
A. Pre-Submissions	3
B. Original Premarket Approval (PMA), Panel-Track Supplements, and Premarket Report Applications	5
C. 180-Day PMA Supplements	5
D. Real-Time PMA Supplements	5
E. De Novo Submissions	7
F. 510(k) Submissions	8
G. CDRH Waiver by Application	9
H. Original Biologics Licensing Application (BLA)	10
I. BLA Priority Supplements	10
J. Original PMA and BLA Priority Supplement Revisions	10
K. BLA Manufacturing Supplement Requiring Prior Approval	10
III. Infrastructure	10
A. Quality Management	10
B. Scientific and Regulatory Review Capacity	11
C. IT Infrastructure for Submission Management	11
D. Training	12
E. Time Experting	12
F. Fee Setting, Fee Collection, and Workload	12
G. Process Improvements	12
IV. Incentive Review	12
A. Deficiency Letters	13
C. Device Accidents	13
D. Enhanced Use of Consensus Standards	13
E. Third Party Review	15
F. Patient Engagement & the Science of Patient Input	16
G. Emerging Diagnostics	17
H. Real World Evidence (RWE)	17
I. Digital Health	19
J. Guidance Document Development	20
K. Total Product Life Cycle (TPLC)	20
V. Independent Assessment of Review Process Management	21

Replaces  
Previous 3P510k Guidances

*Contains Nonbinding Recommendations*

**510(k) Third Party Review Program  
Guidance for Industry,  
Food and Drug Administration Staff,  
and Third Party  
Review Organizations**


Document issued on March 12, 2020

The draft of this document was issued on September 14, 2018

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0910-0375 (expires 11-30-2022).

See additional PRA statement in Section XI of the guidance.

This guidance supersedes “Implementation of Third Party Programs Under the FDA Modernization Act of 1997, Final Guidance for Staff, Industry, and Third Parties” issued on February 3, 2001, and “Guidance for Third Parties and FDA Staff, Third Party Review of Premarket Notifications” issued on September 28, 2004.



**U.S. FOOD & DRUG  
ADMINISTRATION**  
CENTER FOR DEVICES & RADIOLOGICAL HEALTH


U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Devices and Radiological Health

1

# The Review Organization Interacts with Submitters on the FDA's Behalf



# The Program Protects & Promotes Public Health





# Program Updated to Eliminate Routine Re-Review


- Product code eligibility updated to support success
- 3P510k Review Organizations perform FDA-equivalent reviews
- 3P510k Review Organization recognition sunsets every 3 years



# Reviewing the Right Devices



# Reviewing the Right Devices cont.



Half of all 510(k)s submitted to CDRH are eligible for 3P510k review

# We Expect FDA-Equivalent Reviews

1

Ensure device is eligible




2

Assign qualified reviewers



3

Use relevant guidances & information



4

Interact Early with the FDA



5

Review, document & submit to the FDA



# FDA-Equivalent Reviews Explain their Analysis and Recommendation

- Review and assess the submission
  - How do you assess the regulatory question of substantial equivalence?
  - Assess ‘how’ rather than state that a standard or guidance was used
- Organize and submit to the FDA
  - Be sure to include a useful Table of Contents
  - Update the review memo to reflect deficiencies and their resolution

See Section VI of the guidance for more detail

See “The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]”

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k>

# 3P510k Submitters and Review Organizations Have the Same Rights for Dispute Resolution

- Many disputes are often the results of misunderstanding or miscommunication – seek clarification first
- [Center for Devices and Radiological Health Appeals Processes](#)
- [Center for Devices and Radiological Health Appeals Processes: Questions and Answers About 517A](#)
- Complaints can be sent to [3P510k@fda.hhs.gov](mailto:3P510k@fda.hhs.gov)

# Leveraging Global Standards is Least Burdensome

Organizational Behaviors



MDSAP N3

Good Regulatory Review Practices



GRRP N40



**IMDRF** International Medical  
Device Regulators Forum

See Section X of the guidance for more detail  
Link to these documents on Resources Slide #21

# We Clarified Our Expectations of 3P510k Review Organizations

Main takeaway:

- quality, well-documented, FDA-equivalent reviews
- (A) Submissions, communications, and all documentation should be in English
- (B) Impartiality, including not promising FDA clearance
  - See also IMDRF N3
- (C) Training and expertise of review personnel
  - Leverages IMDRF N40
- (D) Controls and records for using external technical expertise
- (E) Maintain confidentiality
- (F) Complaint handling
- (G) Recordkeeping



# We Clarified Suspension and Withdrawal of Recognition

- The act provides exact language in 301(y)(1) for prohibited acts
- We expect 3P510k Review Organizations to demonstrate technical competency
- We will assess and audit 3P510k Review Organizations periodically as necessary
- If needed, we will suspend or withdraw recognition after providing notice and an opportunity for an informal hearing



# Follow Good Business Practices



Document  
& record



Be aware of  
prohibited acts



Maintain  
quality reviews



# Current 3P510k Review Organizations Should Submit Applications to be Recognized by September 12, 2020

- All entities will go through the new recognition process
- Work proactively on your recognition
- Submit your application as soon as practical
- All recognitions sunset after 3 years





# What You Should Include in Your Application to be a Recognized 510(k) Third Party Review Organization


- (1) Administrative Info, including device types
- (2) Policies and procedures to prevent conflicts of interest
- (3) Personnel qualifications
  - Including supervisory personnel
- (4) Certification statements

See Section VIII of the guidance for more detail

Also available at FDA.gov

<https://www.fda.gov/medical-devices/510k-third-party-review-program/how-become-third-party-review-organization>

# The FDA Will Monitor & Audit



# Resources

- 510(k) Third Party Review Program: Final Guidance
  - <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-third-party-review-program>
- 510(k) Third Party Review Program Webpage
  - <https://www.fda.gov/medical-devices/premarket-submissions/510k-third-party-review-program>
- CDRH Learn Modules for the 510(k) Third Party Review Program
  - <https://www.fda.gov/training-and-continuing-education/cdrh-learn#collapseSeven>
- Product Code Classification Database
  - <https://www.fda.gov/medical-devices/classify-your-medical-device/product-code-classification-database>
- Federal Food, Drug, and Cosmetic Act
  - [https://legcounsel.house.gov/Comps/Federal Food, Drug, And Cosmetic Act.pdf](https://legcounsel.house.gov/Comps/Federal%20Food,%20Drug,%20And%20Cosmetic%20Act.pdf)
- IMDRF MDSAP Working Group N3 Final: 2016 (Edition 2): “Requirements for Medical Device Auditing Organizations for Regulatory Authority Recognition”
  - <http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-160324-requirements-auditing-orar.pdf>
- IMDRF/GRRP WG/N40 Final:2017: “Competence, Training, and Conduct Requirements for Regulatory Reviewers”
  - <http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-170316-competence-conduct-reviewers.pdf>

# Questions?

Division of Industry and Consumer Education:

[DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)

Slide Presentation, Transcript and Webinar Recording will be available at:

<http://www.fda.gov/training/cdrhlearn>

Under Heading: 510(k) Third Party Review Program

Please complete a short survey about your FDA CDRH webinar experience. The survey can be found at [www.fda.gov/CDRHWebinar](http://www.fda.gov/CDRHWebinar)

immediately following the conclusion of the live webinar.